<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711424568</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711424568</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Risk factors</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Serum homocysteine and folate but not vitamin B<sub>12</sub> are predictors of CHD mortality in older adults</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gopinath</surname><given-names>Bamini</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711424568">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Flood</surname><given-names>Victoria M</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711424568">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rochtchina</surname><given-names>Elena</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711424568">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Thiagalingam</surname><given-names>Aravinda</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711424568">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mitchell</surname><given-names>Paul</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711424568">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711424568"/>
</contrib>
</contrib-group>
<aff id="aff1-1741826711424568"><label>1</label>University of Sydney, NSW, Australia.</aff>
<aff id="aff2-1741826711424568"><label>2</label>University of Wollongong, Sydney, NSW, Australia.</aff>
<author-notes>
<corresp id="corresp1-1741826711424568">Paul Mitchell, Centre for Vision Research, University of Sydney, Westmead Hospital, Hawkesbury Rd, Westmead, NSW, 2145, Australia Email: <email>paul_mitchell@wmi.usyd.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>1420</fpage>
<lpage>1429</lpage>
<history>
<date date-type="received"><day>23</day><month>6</month><year>2011</year></date>
<date date-type="accepted"><day>5</day><month>9</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Aims:</bold> The associations of serum levels of homocysteine (tHcy), vitamin B<sub>12</sub>, and folate with risk of all-cause and coronary heat disease (CHD) mortality is controversial, and the evidence in older adults is limited. The aim of this study was to examine whether serum folate, vitamin B<sub>12</sub>, and tHcy independently predict risk of CHD-related and all-cause mortality in older adults.</p>
<p><bold>Methods and results:</bold> Serum concentrations of folate, vitamin B<sub>12</sub>, and tHcy were determined from blood samples obtained from 3010 Blue Mountains Eye Study participants (1997–99), aged ≥55 years. CHD and all-cause mortality was confirmed using the Australian National Death Index.</p>
<p><bold>Results:</bold> Persons in the highest quartile of serum tHcy had increased risk of CHD mortality compared to those in the lowest quartile (multivariable-adjusted hazard ratio, HR, 2.45, 95% CI 1.30–4.62). A significant continuous association was observed between serum tHcy and CHD mortality (HR per SD ( = 4.8 µmol/l) increase in serum tHcy 1.25, 95% CI 1.08–1.45), after multivariable-adjustment. A significant association between folate deficiency and CHD-mortality was found (multivariable-adjusted HR 1.53, 95% CI 1.01–2.29). Hyperhomocysteinaemia (&gt;15 µmol/l) was a significant predictor of all-cause mortality (multivariable-adjusted HR 1.47, 95% CI 1.18–1.83). A significant interaction was observed between hyperhomocysteinaemia and folate deficiency for all-cause and CHD mortality (<italic>p</italic> for interaction = 0.03 and <italic>p</italic> for interaction = 0.05, respectively).</p>
<p><bold>Conclusion:</bold> Serum tHcy and folate were independent predictors of CHD and all-cause mortality, while vitamin B<sub>12</sub> was not associated. As raised tHcy levels and folate deficiency are associated with poorer lifestyle, changes to a more healthful lifestyle among older adults may minimize the adverse vascular effects of elevated tHcy.</p>
</abstract>
<kwd-group>
<kwd>All-cause mortality</kwd>
<kwd>Blue Mountains Eye Study</kwd>
<kwd>coronary heart disease</kwd>
<kwd>folate</kwd>
<kwd>homocysteine</kwd>
<kwd>incidence</kwd>
<kwd>mortality</kwd>
<kwd>older adults</kwd>
<kwd>vitamin B<sub>12</sub></kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711424568" sec-type="intro"><title>Introduction</title>
<p>Coronary heart disease (CHD) remains the leading cause of death worldwide and generates a substantial economic burden.<sup><xref ref-type="bibr" rid="bibr1-1741826711424568">1</xref></sup> Traditional risk factors such as hyperlipidaemia, smoking, hypertension, and diabetes are thought to explain most CHD<sup><xref ref-type="bibr" rid="bibr2-1741826711424568">2</xref>,<xref ref-type="bibr" rid="bibr3-1741826711424568">3</xref></sup> and 15–20% of those with CHD have no identified traditional risk factors and miss the opportunity for primary prevention.<sup><xref ref-type="bibr" rid="bibr3-1741826711424568">3</xref>,<xref ref-type="bibr" rid="bibr4-1741826711424568">4</xref></sup> Elevated circulating total homocysteine (tHcy) levels is a potential candidate,<sup><xref ref-type="bibr" rid="bibr5-1741826711424568">5</xref>,<xref ref-type="bibr" rid="bibr6-1741826711424568">6</xref></sup> which is influenced mainly by blood levels of cyanocobalamin (vitamin B<sub>12</sub>), folic acid (vitamin B<sub>9</sub>), and pyridoxine (vitamin B<sub>6</sub>).<sup><xref ref-type="bibr" rid="bibr7-1741826711424568">7</xref></sup></p>
<p>There is some uncertainty regarding the strength of association between tHcy and risk of CHD and CVD,<sup><xref ref-type="bibr" rid="bibr8-1741826711424568">8</xref></sup> particularly in older adults.<sup><xref ref-type="bibr" rid="bibr9-1741826711424568">9</xref></sup> Some prospective studies showed a strong association between tHcy and CVD,<sup><xref ref-type="bibr" rid="bibr10-1741826711424568">10</xref>–<xref ref-type="bibr" rid="bibr14-1741826711424568">14</xref></sup> some found weaker associations,<sup><xref ref-type="bibr" rid="bibr15-1741826711424568">15</xref>,<xref ref-type="bibr" rid="bibr16-1741826711424568">16</xref></sup> while others, including the Atherosclerosis Risk in Communities Study,<sup><xref ref-type="bibr" rid="bibr17-1741826711424568">17</xref>,<xref ref-type="bibr" rid="bibr18-1741826711424568">18</xref></sup> failed to demonstrate any association. Moreover, whereas the evidence for the associations of folate or vitamin B<sub>12</sub> status with CVD and CHD mortality in middle-aged individuals remains equivocal,<sup><xref ref-type="bibr" rid="bibr17-1741826711424568">17</xref>,<xref ref-type="bibr" rid="bibr19-1741826711424568">19</xref>,<xref ref-type="bibr" rid="bibr20-1741826711424568">20</xref></sup> the data are even more inconsistent and limited among older adults (<xref ref-type="table" rid="table1-1741826711424568">Table 1</xref>). Only two cohort studies of older adults<sup><xref ref-type="bibr" rid="bibr9-1741826711424568">9</xref>,<xref ref-type="bibr" rid="bibr21-1741826711424568">21</xref></sup> have simultaneously examined the link between serum tHcy, folate, and vitamin B<sub>12</sub> with both total and/or CVD mortality (<xref ref-type="table" rid="table1-1741826711424568">Table 1</xref>). However, these studies were relatively small and were only able to demonstrate a significant positive association between tHcy and mortality, not for serum folate or vitamin B<sub>12</sub>.
<table-wrap id="table1-1741826711424568" position="float"><label>Table 1.</label><caption><p>Cohort studies of older adults examining the association between serum total homocysteine, folate, and/or vitamin B<sub>12</sub> with total and/or cardiovascular disease mortality</p></caption>
<graphic alternate-form-of="table1-1741826711424568" xlink:href="10.1177_1741826711424568-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Study</th>
<th>Age (years)</th>
<th>Sample size</th>
<th>Relevant study factors</th>
<th>Study outcome(s)</th>
<th>Finding</th></tr></thead>
<tbody align="left">
<tr>
<td align="justify">Framingham (USA)<sup><xref ref-type="bibr" rid="bibr39-1741826711424568">39</xref></sup></td>
<td align="justify">Men and women, mean 71</td>
<td align="justify">1933</td>
<td align="justify">Serum tHcy</td>
<td align="justify">CVD and total mortality</td>
<td align="justify">Elevated tHcy associated with increased risk of total and CVD mortality</td></tr>
<tr>
<td align="justify">Northern Manhattan Study (USA)<sup><xref ref-type="bibr" rid="bibr40-1741826711424568">40</xref></sup></td>
<td align="justify">Men and women, mean 69</td>
<td align="justify">2939</td>
<td align="justify">Serum tHcy</td>
<td align="justify">CVD mortality</td>
<td align="justify">tHcy was a strong predictor of vascular death</td></tr>
<tr>
<td align="justify">Zutphen Elderly Study (The Netherlands)<sup><xref ref-type="bibr" rid="bibr41-1741826711424568">41</xref></sup></td>
<td align="justify">Men, mean 71</td>
<td align="justify">878</td>
<td align="justify">Serum tHcy</td>
<td align="justify">CHD and stroke mortality</td>
<td align="justify">tHcy was not significantly associated with CHD or stroke mortality</td></tr>
<tr>
<td align="justify">Hordaland Homocysteine Study (Norway)<sup><xref ref-type="bibr" rid="bibr10-1741826711424568">10</xref></sup></td>
<td align="justify">Men and women, 65−67</td>
<td align="justify">2127 men and 2639 women</td>
<td align="justify">Serum tHcy</td>
<td align="justify">Total and CVD mortality</td>
<td align="justify">tHcy was a strong predictor of total and CVD mortality</td></tr>
<tr>
<td align="justify">Leiden 85-plus study (the Netherlands)<sup><xref ref-type="bibr" rid="bibr11-1741826711424568">11</xref></sup></td>
<td align="justify">Men and women, 85</td>
<td align="justify">302</td>
<td align="justify">Serum tHcy and folic acid</td>
<td align="justify">CVD mortality</td>
<td align="justify">tHcy was a strong predictor of CVD mortality but not folic acid</td></tr>
<tr>
<td align="justify">Medical Research Council Trial of Assessment and Management of Older People (UK)<sup><xref ref-type="bibr" rid="bibr9-1741826711424568">9</xref></sup></td>
<td align="justify">Men and women, ≥75</td>
<td align="justify">853</td>
<td align="justify">Plasma tHcy, folate, and vitamin B<sub>12</sub></td>
<td align="justify">Total and CVD mortality</td>
<td align="justify">tHcy (but not folate or B<sub>12</sub>) was associated with total and CVD mortality</td></tr>
<tr>
<td align="justify">Spain<sup><xref ref-type="bibr" rid="bibr42-1741826711424568">42</xref></sup></td>
<td align="justify">Men and women, ≥60</td>
<td align="justify">215</td>
<td align="justify">Serum tHcy, folate, and vitamin B<sub>12</sub></td>
<td align="justify">Total mortality</td>
<td align="justify">tHcy (but not folate or B<sub>12</sub>) was associated with total mortality</td></tr>
<tr>
<td align="justify">Finland<sup><xref ref-type="bibr" rid="bibr43-1741826711424568">43</xref></sup></td>
<td align="justify">Men and women, ≥65</td>
<td align="justify">344</td>
<td align="justify">Serum folate and vitamin B<sub>12</sub></td>
<td align="justify">CVD mortality</td>
<td align="justify">Low serum vitamin B<sub>12</sub> levels associated with increased risk of CVD mortality</td></tr>
<tr>
<td align="justify">British National Diet and Nutrition Survey (community-living subset) of People Aged 65 Years and Over (UK)<sup><xref ref-type="bibr" rid="bibr21-1741826711424568">21</xref></sup></td>
<td align="justify">Men and women, mean 76.7</td>
<td align="justify">1100</td>
<td align="justify">Serum tHcy, folate, and vitamin B<sub>12</sub></td>
<td align="justify">Total and CVD mortality</td>
<td align="justify">tHcy (but not folate or B<sub>12</sub>) was associated with higher risk of CVD and total mortality</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711424568"><p>CHD, coronary heart disease; CVD, cardiovascular disease; tHcy, homocysteine.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>We aimed to explore associations of serum levels of folate, vitamin B<sub>12</sub>, and tHcy with both all-cause and CHD mortality in a large Australian cohort of adults aged ≥55 years. To best of our knowledge, this is the largest cohort study of older adults to simultaneously examine the relationships between serum tHcy, folate, and vitamin B<sub>12</sub> with both all-cause and CHD mortality.</p>
</sec>
<sec id="sec2-1741826711424568" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711424568"><title>Study population</title>
<p>The Blue Mountains Eye Study (BMES) is a population-based cohort study of vision and common eye diseases in a suburban Australian population 49 years and older at baseline. The study was approved by the Human Research Ethics Committee of the University of Sydney and was conducted adhering to the tenets of the Declaration of Helsinki. Signed informed consent was obtained from all participants at each examination.</p>
<p>Survey methods have been described previously.<sup><xref ref-type="bibr" rid="bibr22-1741826711424568">22</xref></sup> Briefly, baseline examinations of 3654 residents older than 49 years were conducted during 1992–94 (BMES-1, 82.4% participation rate). Surviving baseline participants were invited to attend 5-year follow-up examinations (1997–99, BMES-2), at which 2334 (75.1% of survivors) and an additional 1174 newly eligible residents were examined i.e. those who had moved into the study area or study age group. At the 10-year follow up (2002–04, BMES-3), 1952 participants (75.6% of survivors) were re-examined.</p>
</sec>
<sec id="sec4-1741826711424568"><title>Ascertainment of CVD and related risk factors</title>
<p>Medical and smoking histories were determined by interviewer-administered questionnaire at baseline. A history of angina, myocardial infarction, diabetes mellitus, hypertension, stroke, or cancer was determined by responses to questions starting with ‘Has a doctor advised you that you have … ?’ History of smoking was defined as never, past, or current smoking. Current smokers included those who had stopped smoking within the past year. Alcohol intake was assessed by questions about the frequency of consuming alcoholic drinks (days per week), and consumption was split into three groups (no alcohol, 0–20 g, &gt;20 g). Weight in kilograms, height in meters, and systolic and diastolic blood pressures were also recorded at baseline.</p>
<p>Classification of hypertension was based on the 2003 World Health Organization/International Society of Hypertension guidelines.<sup><xref ref-type="bibr" rid="bibr23-1741826711424568">23</xref></sup> Participants were classified as having hypertension stage 1 if systolic blood pressure was 140–159 mmHg or diastolic blood pressure was 90–99 mmHg. Participants were classified as having hypertension stage 2 if they were previously diagnosed with hypertension and were using antihypertensive medications, if systolic blood pressure was ≥160 mmHg, or diastolic blood pressure was ≥100 mmHg at examination. Body mass index was calculated as weight in kilograms divided by height in meters squared, with &lt;20 kg/m<sup>2</sup> defined as low. Disability in walking at baseline was assessed based on a trained examiner's observations of the participant having walking difficulties or used walking aids or a wheelchair.</p>
</sec>
<sec id="sec5-1741826711424568"><title>Serum measurement and analyses</title>
<p>Of 3508 participants examined in the second cross-section (at BMES-2), fasting blood samples were drawn from 3010 subjects within 4 weeks of the day of examination. Blood testing was performed on the same day as blood collection, at the Institute of Clinical Pathology and Medical Research (ICPMR) laboratory, at Westmead Hospital, Australia. tHcy was determined from blood using the fluorescent polarization immunoassay method on an IMx Analyser. Hyperhomocysteinemia was defined as &gt;15 µmol/l, a laboratory recommended cut-off for older adults. Serum vitamin B<sub>12</sub> and folate and red-cell folate assays were performed using the competitive-binding assay method, conducted on a Beckman-Access Analyser. Individuals were classified as having low serum vitamin B<sub>12</sub> if serum levels were &lt;150 pmol/l. Individuals were classified as having low serum folate if serum levels were &lt;11 nmol/l.<sup><xref ref-type="bibr" rid="bibr24-1741826711424568">24</xref>,<xref ref-type="bibr" rid="bibr25-1741826711424568">25</xref></sup> Serum creatinine was measured using a Hitachi 747 biochemistry analyser (Roche, <ext-link ext-link-type="uri" xlink:href="http://www.rochediagnostics.com.au/">http://www.rochediagnostics.com.au/</ext-link>)..</p>
</sec>
<sec id="sec6-1741826711424568"><title>Mortality data</title>
<p>To identify and confirm persons who died after baseline examinations, demographic information including surname, first and second names, gender, and birthdates of the 3010 participants were cross-matched with Australian National Death Index (NDI) data for deaths. A probabilistic record linkage package was used, adopting a multiple pass procedure in which both data sets were grouped based on different characteristics (e.g. date of birth, name, sex) each time. Matches were divided into exact and non-exact. All non-exact matched records were examined manually and accepted if there was only one non-exact matched characteristic that was not critical. Information provided by family members during follow up was also included if the participant was reported to have died on or before December 2007. The International Classification of Diseases, ninth revision<sup><xref ref-type="bibr" rid="bibr26-1741826711424568">26</xref></sup> and International Statistical Classification of Diseases, tenth revision<sup><xref ref-type="bibr" rid="bibr27-1741826711424568">27</xref></sup> cause-of-death codes were also obtained. CHD mortality was defined using the following codes from ICD-9 (410.0–9, 411.0–8, 412, 414.0–9) and ICD-10 (I21.0–9, I22.0–9, I23.0–8, I24.0–9, I25.0–9).<sup><xref ref-type="bibr" rid="bibr28-1741826711424568">28</xref></sup> The validity of Australian NDI data has been reported to have high sensitivity and specificity for cardiovascular mortality (92.5% and 89.6%, respectively).<sup><xref ref-type="bibr" rid="bibr29-1741826711424568">29</xref></sup> The census cut-off point for CHD and all-cause mortality was 31 December 2007 (10-year follow up).</p>
</sec>
<sec id="sec7-1741826711424568"><title>Statistical analysis</title>
<p>SAS statistical software (SAS Institute, Cary NC, USA) version 9.1 was used for analyses. The association between tHcy, folate, and vitamin B<sub>12</sub>, and mortality were examined with Cox regression models to estimate hazard ratios (HR) and 95% confidence intervals (CI). Multivariate regression models were first adjusted for age and sex, and then further adjusted for confounders that were found to be significantly associated with mortality, i.e. body mass index, serum creatinine, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction. We did not adjust for serum cholesterol as this variable was not associated with CHD mortality in our population.<sup><xref ref-type="bibr" rid="bibr28-1741826711424568">28</xref></sup> We studied tHcy, folate, and vitamin B<sub>12</sub> both as categorized (quartiles using the lowest quartiles as reference group and diagnostic/clinical cut-points) and as continuous (per standard deviation, SD) variables. We tested for interaction effects, using a likelihood-ratio test, by including a product term between hyperhomocysteinaemia and folate deficiency in the analysis. Statistical significance was defined as <italic>p</italic>&lt;0.05.</p>
</sec>
</sec>
<sec id="sec8-1741826711424568" sec-type="results"><title>Results</title>
<p>Analyses involved the 3010 BMES-2 participants who had fasting blood samples. Baseline characteristics of the participants included in this study are shown in <xref ref-type="table" rid="table2-1741826711424568">Table 2</xref>. We found that those subjects with elevated tHcy (&gt;15 µmol/l) were more likely to be male, older, non-alcohol drinkers and to have low BMI, poor self-rated health, walking disability, hypertension, diabetes, angina, stroke, and AMI, higher serum creatinine, and lower serum folate and vitamin B<sub>12</sub> concentrations.
<table-wrap id="table2-1741826711424568" position="float"><label>Table 2.</label><caption><p>Descriptive baseline characteristics of Blue Mountains Eye Study participants stratified by diagnostic cut-points of total serum homocysteine</p></caption>
<graphic alternate-form-of="table2-1741826711424568" xlink:href="10.1177_1741826711424568-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Characteristics</th>
<th colspan="2">Serum homocysteine (µmol/l)<hr/></th>
<th rowspan="2">Unadjusted <italic>p</italic>-value</th></tr>
<tr><th>≤15 (<italic>n</italic> = 2455)</th>
<th>&gt;15 (<italic>n</italic> = 493)</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>65.6 ± 8.9</td>
<td>72.2 ± 9.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Male sex</td>
<td>1007 (41.0)</td>
<td>264 (53.6)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Low qualifications</td>
<td>1496 (60.9)</td>
<td>265 (53.8)</td>
<td>0.003</td></tr>
<tr>
<td>Current smoking status</td>
<td>219 (8.9)</td>
<td>56 (11.4)</td>
<td>0.08</td></tr>
<tr>
<td colspan="4">Alcohol consumption (g/day)</td></tr>
<tr>
<td> None</td>
<td>388 (18.2)</td>
<td>115 (27.6)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> 0⊟20</td>
<td>1339 (62.7)</td>
<td>229 (54.9)</td>
<td/></tr>
<tr>
<td> &gt;20</td>
<td>408 (19.1)</td>
<td>73 (17.5)</td>
<td/></tr>
<tr>
<td>Low body mass index</td>
<td>59 (2.4)</td>
<td>23 (4.8)</td>
<td>0.001</td></tr>
<tr>
<td>Poor self-rated health</td>
<td>423 (17.3)</td>
<td>138 (28.2)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Walking disability</td>
<td>135 (5.5)</td>
<td>82 (16.6)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>82.7 ± 16.0</td>
<td>105.0 ± 36.7</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Serum folate (nmol/l)</td>
<td>19.1 ± 8.8</td>
<td>13.9 ± 8.2</td>
<td>&lt;0.0001</td></tr>
<tr>
<td>Serum vitamin B<sub>12</sub> (pmol/l)</td>
<td>297.8 ± 155.1</td>
<td>223.6 ± 134.3</td>
<td>&lt;0.0001</td></tr>
<tr>
<td colspan="4">Disease</td></tr>
<tr>
<td> Hypertension</td>
<td>1201 (49.1)</td>
<td>312 (63.5)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Diabetes</td>
<td>247 (10.1)</td>
<td>74 (15.0)</td>
<td>0.001</td></tr>
<tr>
<td colspan="4">History</td></tr>
<tr>
<td> Diagnosed cancer</td>
<td>277 (11.3)</td>
<td>45 (9.3)</td>
<td>0.20</td></tr>
<tr>
<td> Angina</td>
<td>219 (8.9)</td>
<td>79 (16.3)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Stroke</td>
<td>85 (3.5)</td>
<td>43 (8.9)</td>
<td>&lt;0.0001</td></tr>
<tr>
<td> Acute myocardial infarction</td>
<td>159 (6.5)</td>
<td>65 (13.4)</td>
<td>&lt;0.0001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711424568"><p>Values are mean ± SD or <italic>n</italic> (%).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Persons in the highest quartile of serum tHcy had twice the risk of CHD mortality compared to those in the lowest quartile (multivariable-adjusted HR 2.15, 95% CI 1.12–4.11, <italic>p</italic> for trend = 0.02). Of those with elevated tHcy (&gt;15 µmol/l), 15% died of CHD compared to 5% of participants with normal serum tHcy (<xref ref-type="table" rid="table3-1741826711424568">Table 3</xref>). Hyperhomocysteinaemia and folate deficiency predicted a 58% and 53% increased risk of CHD mortality, respectively (<xref ref-type="table" rid="table4-1741826711424568">Table 4</xref>). We also found no significant association between quartiles of red cell folate and risk of CHD mortality (<italic>p</italic> for trend = 0.49). We observed a marginally significant association between serum tHcy as a continuous variable and risk of CHD mortality (HR per SD ( = 4.8 µmol/l) increase in serum tHcy 1.18, 95% CI 0.99–1.39), after multivariate adjustment. No significant associations between serum folate, red-cell folate, vitamin B<sub>12</sub>, and CHD mortality were observed (data not shown).
<table-wrap id="table3-1741826711424568" position="float"><label>Table 3.</label><caption><p>Coronary heart disease mortalities (over 10 years) by quartiles of total serum homocysteine, folate, and vitamin B<sub>12</sub></p></caption>
<graphic alternate-form-of="table3-1741826711424568" xlink:href="10.1177_1741826711424568-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Serum levels</th>
<th><italic>n</italic></th>
<th>Age- and sex-adjusted</th>
<th>Multivariable-adjusted<sup><xref ref-type="table-fn" rid="table-fn3-1741826711424568">a</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Homocysteine (µmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤9.0</td>
<td>865</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 10.0–11.0</td>
<td>723</td>
<td>1.08 (0.58–1.98)</td>
<td>1.51 (0.74–3.08)</td></tr>
<tr>
<td> 3rd quartile, 12.0–13.0</td>
<td>555</td>
<td>1.78 (1.00–3.16)</td>
<td>1.68 (0.83–3.41)</td></tr>
<tr>
<td> 4th quartile, ≥14.0</td>
<td>805</td>
<td>2.66 (1.58–4.47)</td>
<td>2.15 (1.12–4.11)</td></tr>
<tr>
<td> <italic>p</italic> for trend</td>
<td/>
<td>&lt;0.0001</td>
<td>0.02</td></tr>
<tr>
<td colspan="4">Folate (nmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤11.99</td>
<td>703</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 12.00–15.96</td>
<td>740</td>
<td>1.66 (1.10–2.52)</td>
<td>1.36 (0.82–2.25)</td></tr>
<tr>
<td> 3rd quartile, 16.00–22.40</td>
<td>779</td>
<td>1.14 (0.73–1.78)</td>
<td>1.22 (0.71–2.07)</td></tr>
<tr>
<td> 4th quartile, ≥22.44</td>
<td>741</td>
<td>1.10 (0.71–1.70)</td>
<td>0.96 (0.56–1.62)</td></tr>
<tr>
<td> <italic>p</italic> for trend</td>
<td/>
<td>0.03</td>
<td>0.21</td></tr>
<tr>
<td colspan="4">Vitamin B<sub>12</sub> (pmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤189</td>
<td>743</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 190.0–255.0</td>
<td>743</td>
<td>0.96 (0.64–1.42)</td>
<td>0.72 (0.46–1.15)</td></tr>
<tr>
<td> 3rd quartile, 256.0–335.0</td>
<td>738</td>
<td>1.10 (0.73–1.66)</td>
<td>0.79 (0.48–1.28)</td></tr>
<tr>
<td> 4th quartile, ≥336.0</td>
<td>739</td>
<td>0.80 (0.52–1.25)</td>
<td>0.76 (0.45–1.29)</td></tr>
<tr>
<td> <italic>p</italic> for trend</td>
<td/>
<td>0.96</td>
<td>0.16</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711424568"><p>Values are hazard ratio (95% confidence interval). <sup>a</sup>Further adjusted for body mass index, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, serum creatinine, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1741826711424568" position="float"><label>Table 4.</label><caption><p>Coronary heart disease mortalities (over 10 years) by diagnostic cut-points of total serum homocysteine, folate, and vitamin B<sub>12</sub></p></caption>
<graphic alternate-form-of="table4-1741826711424568" xlink:href="10.1177_1741826711424568-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Serum levels</th>
<th>Mortalities/at risk</th>
<th>Age- and sex-adjusted</th>
<th>Multivariable-adjusted<sup>a</sup></th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Homocysteine (µmol/l)</td></tr>
<tr>
<td> ≤15</td>
<td>108/2401</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &gt;15</td>
<td>71/474</td>
<td>2.11 (1.54–2.88)</td>
<td>1.58 (1.05–2.37)</td></tr>
<tr>
<td colspan="4">Folate (nmol/l)</td></tr>
<tr>
<td> ≥11</td>
<td>130/2357</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &lt;11</td>
<td>48/529</td>
<td>1.70 (1.22–2.38)</td>
<td>1.53 (1.01–2.29)</td></tr>
<tr>
<td colspan="4">Vitamin B<sub>12</sub> (pmol/l)</td></tr>
<tr>
<td> ≥150</td>
<td>156/2537</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &lt;150</td>
<td>22/349</td>
<td>0.77 (0.49–1.21)</td>
<td>0.69 (0.40–1.18)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1741826711424568"><p>Values are hazard ratio (95% confidence interval). <sup>a</sup>Further adjusted for body mass index, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, serum creatinine, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction.</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="table" rid="table5-1741826711424568">Table 5</xref> shows that subjects in the highest quartile of serum tHcy had a 54% increased risk of all-cause mortality compared to participants in the lowest quartiles (<italic>p</italic> for trend = 0.002). <xref ref-type="table" rid="table6-1741826711424568">Table 6</xref> shows that hyperhomocysteinaemia was a significant predictor of all-cause mortality (multivariable-adjusted HR 1.47, 95% CI 1.18–1.83). Folate deficiency significantly increased the risk of all-cause mortality by 31% (<xref ref-type="table" rid="table6-1741826711424568">Table 6</xref>). <xref ref-type="fig" rid="fig1-1741826711424568">Figure 1</xref> shows the 10-year survival of BMES participants by diagnostic cut-points of serum tHcy and folate. Older persons with elevated tHcy or a folate deficiency had lower survival. A significant continuous association was observed between serum tHcy and risk of all-cause mortality (HR 1.18, 95% CI 1.08–1.30). There was no significant continuous association between red-cell folate and all-cause mortality (multivariable-adjusted HR 1.11, 95% CI 0.92–1.33).
<table-wrap id="table5-1741826711424568" position="float"><label>Table 5.</label><caption><p>All-cause 10-year mortality by quartiles of total serum homocysteine, folate, and vitamin B<sub>12</sub></p></caption>
<graphic alternate-form-of="table5-1741826711424568" xlink:href="10.1177_1741826711424568-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Serum levels</th>
<th><italic>n</italic></th>
<th>Age- and sex-adjusted</th>
<th>Multivariable-adjusted<sup>a</sup></th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Homocysteine (µmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤9.0</td>
<td>865</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 10.0–11.0</td>
<td>723</td>
<td>0.98 (0.74–1.31)</td>
<td>1.16 (0.84–1.60)</td></tr>
<tr>
<td> 3rd quartile, 12.0–13.0</td>
<td>555</td>
<td>1.22 (0.92–1.61)</td>
<td>1.29 (0.93–1.78)</td></tr>
<tr>
<td> 4th quartile, ≥14.0</td>
<td>805</td>
<td>1.81 (1.42–2.31)</td>
<td>1.54 (1.14–2.08)</td></tr>
<tr>
<td> <italic>p</italic> for trend</td>
<td/>
<td>&lt;0.0001</td>
<td>0.002</td></tr>
<tr>
<td colspan="4">Folate (nmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤11.99</td>
<td>703</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 12.00–15.96</td>
<td>740</td>
<td>1.42 (1.14–1.76)</td>
<td>1.25 (0.97–1.62)</td></tr>
<tr>
<td> 3rd quartile, 16.00–22.40</td>
<td>779</td>
<td>0.94 (0.74–1.19)</td>
<td>1.10 (0.84–1.44)</td></tr>
<tr>
<td> 4th quartile, ≥22.44</td>
<td>741</td>
<td>0.92 (0.73–1.16)</td>
<td>0.95 (0.73–1.24)</td></tr>
<tr>
<td> <italic>P</italic> for trend</td>
<td/>
<td>0.01</td>
<td>0.09</td></tr>
<tr>
<td colspan="4">Vitamin B<sub>12</sub> (pmol/l)</td></tr>
<tr>
<td> 1st quartile, ≤189</td>
<td>743</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> 2nd quartile, 190.0–255.0</td>
<td>743</td>
<td>1.07 (0.86–1.32)</td>
<td>1.04 (0.82–1.33)</td></tr>
<tr>
<td> 3rd quartile, 256.0–335.0</td>
<td>738</td>
<td>1.04 (0.83–1.31)</td>
<td>0.96 (0.74–1.24)</td></tr>
<tr>
<td> 4th quartile, ≥336.0</td>
<td>739</td>
<td>0.83 (0.65–1.06)</td>
<td>0.95 (0.73–1.25)</td></tr>
<tr>
<td> <italic>p</italic> for trend</td>
<td/>
<td>0.39</td>
<td>0.80</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1741826711424568"><p>Values are hazard ratio (95% confidence interval). <sup>a</sup>Further adjusted for body mass index, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, serum creatinine, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table6-1741826711424568" position="float"><label>Table 6.</label><caption><p>All-cause 10-year mortality by diagnostic cut-points of total serum homocysteine, folate, and vitamin B<sub>12</sub></p></caption>
<graphic alternate-form-of="table6-1741826711424568" xlink:href="10.1177_1741826711424568-table6.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Serum levels</th>
<th>Mortalities/at risk</th>
<th>Age- and sex-adjusted</th>
<th>Multivariable-adjusted<sup>a</sup></th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4">Homocysteine (µmol/l)</td></tr>
<tr>
<td> ≤15</td>
<td>394/2455</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &gt;15</td>
<td>212/493</td>
<td>1.90 (1.60–2.26)</td>
<td>1.47 (1.18–1.83)</td></tr>
<tr>
<td colspan="4">Folate (nmol/l)</td></tr>
<tr>
<td> ≥11</td>
<td>449/2412</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &lt;11</td>
<td>160/551</td>
<td>1.61 (1.35–1.93)</td>
<td>1.31 (1.05–1.62)</td></tr>
<tr>
<td colspan="4">Vitamin B<sub>12</sub> (pmol/l)</td></tr>
<tr>
<td> ≥150</td>
<td>513/2599</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td> &lt;150</td>
<td>96/364</td>
<td>1.02 (0.82–1.27)</td>
<td>1.02 (0.79–1.31)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-1741826711424568"><p>Values are hazard ratio (95% confidence interval). <sup>a</sup>Further adjusted for body mass index, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, serum creatinine, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>The interaction term was significant between hyperhomocysteinaemia (&gt;15 µmol/l) and folate deficiency (&lt;11 nmol/l) for all-cause and CHD mortality (<italic>p</italic> interaction = 0.03 and <italic>p</italic> interaction = 0.05, respectively). Having a folate deficiency in addition to having hyperhomocysteinaemia did not significantly increase the risk of all-cause or CHD mortality (<xref ref-type="table" rid="table7-1741826711424568">Table 7</xref>).
<table-wrap id="table7-1741826711424568" position="float"><label>Table 7.</label><caption><p>Association between combinations of hyperhomocysteinaemia (&gt;15 µmol/l) and folate deficiency (&lt;11 mol/l) and risk of 10-year coronary heart disease (CHD) and all-cause mortality</p></caption>
<graphic alternate-form-of="table7-1741826711424568" xlink:href="10.1177_1741826711424568-table7.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Serum levels</th>
<th colspan="2">CHD<hr/></th>
<th colspan="2">All-cause<hr/></th></tr>
<tr><th>Mortalities/at risk</th>
<th>Multivariable-adjusted<sup>a</sup></th>
<th>Mortalities/at risk</th>
<th>Multivariable-adjusted<sup>a</sup></th></tr></thead>
<tbody align="left">
<tr>
<td>Normal serum folate and homocysteine</td>
<td>85/2042</td>
<td>1.0 (Reference)</td>
<td>319/2088</td>
<td>1.0 (Reference)</td></tr>
<tr>
<td>Hyperhomocysteinaemia and normal folate</td>
<td>43/270</td>
<td>1.85 (1.14–3.02)</td>
<td>119/276</td>
<td>1.61 (1.23–2.11)</td></tr>
<tr>
<td>Normal homocysteine and folate deficiency</td>
<td>20/319</td>
<td>2.07 (1.18–3.64)</td>
<td>66/327</td>
<td>1.53 (1.12–2.08)</td></tr>
<tr>
<td>Hyperhomocysteinaemia and folate deficiency</td>
<td>27/198</td>
<td>1.69 (0.96–2.98)</td>
<td>91/210</td>
<td>1.50 (1.12–2.02)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1741826711424568"><p>Values are hazard ratio (95% confidence interval). <sup>a</sup>Further adjusted for body mass index, current smoking status, alcohol consumption, poor self-rated health, walking disability, qualifications, presence of hypertension and/or diabetes, history of cancer, angina, stroke, and acute myocardial infarction.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec9-1741826711424568" sec-type="discussion"><title>Discussion</title>
<p>To the best of our knowledge, these findings are novel, in that this is the first cohort study of older adults to demonstrate that hyperhomocysteinaemia and folate deficiency are significant, independent predictors of both all-cause and CHD mortality. However, serum vitamin B<sub>12</sub> was not a significant predictor of mortality. Stratified analyses demonstrated that having a folate deficiency in addition to hyperhomocysteinaemia did not significantly increase the risk of all-cause or CHD mortality.</p>
<p>The risk of all-cause mortality increased approximately 18% for each 5 µmol/l increase in serum tHcy, and the presence of hyperhomocysteinaemia in this cohort of older adults was a significant and independent predictor of CHD mortality. These findings agree with a recent meta-analysis,<sup><xref ref-type="bibr" rid="bibr4-1741826711424568">4</xref></sup> which showed that the risk of any CHD event increased approximately 20% for each 5 µmol/l increase in tHcy. The association between tHcy and mortality is relatively well established at least among younger adults; however, only a few prospective studies of older adults have provided support for a causal association. The Leiden 85-Plus Study of 389 subjects demonstrated that of the new biomarkers studied, tHcy had the greatest predictive power (area under receiver operating curve 0.65, 95% CI 0.55–0.75).<sup><xref ref-type="bibr" rid="bibr11-1741826711424568">11</xref></sup> A recent UK study of 853 men and women aged ≥75 years showed that in individuals with plasma tHcy levels in the top third compared to those in the bottom third had a two-fold higher risk of all-cause and CVD mortality.<sup><xref ref-type="bibr" rid="bibr9-1741826711424568">9</xref></sup></p>
<p>Although tHcy accurately predicted CHD and all-cause mortality in older adults from the BMES, lowering tHcy levels may not necessarily be beneficial. It is unclear whether a raised level of tHcy causes CHD and CVD, or whether it is simply a surrogate marker of poor health or health-seeking behaviour.<sup><xref ref-type="bibr" rid="bibr30-1741826711424568">30</xref></sup> Lifestyle modifications may be more beneficial as raised tHcy levels are associated with poorer lifestyles.<sup><xref ref-type="bibr" rid="bibr30-1741826711424568">30</xref>,<xref ref-type="bibr" rid="bibr31-1741826711424568">31</xref></sup> In our cohort we previously showed that a lower diet quality was associated with higher serum tHcy levels.<sup><xref ref-type="bibr" rid="bibr32-1741826711424568">32</xref></sup> A healthful lifestyle that includes an increased intake of fruits, vegetables, and fortified grains and cereals, would not only lower tHcy concentrations but, more importantly, would promote good health regardless of whether tHcy is a cause or maker of disease.<sup><xref ref-type="bibr" rid="bibr30-1741826711424568">30</xref></sup></p>
<p>Older adults with a folate deficiency were at significantly higher risk of CHD and all-cause mortality than those with normal serum folate levels. Given that deficiency in folate is one of the most common causes for mild to moderately elevated tHcy,<sup><xref ref-type="bibr" rid="bibr33-1741826711424568">33</xref></sup> serum folate could influence risk of mortality. Our findings are supported by the ARIC study<sup><xref ref-type="bibr" rid="bibr17-1741826711424568">17</xref></sup> and a small clinic-based study<sup><xref ref-type="bibr" rid="bibr20-1741826711424568">20</xref></sup> which showed evidence of a weak threshold effect with only those with the very lowest folate concentrations being at a higher risk of mortality. Neither our study nor the two other prior studies<sup><xref ref-type="bibr" rid="bibr17-1741826711424568">17</xref>,<xref ref-type="bibr" rid="bibr20-1741826711424568">20</xref></sup> observed a gradual increase in risk with declining folate concentration.</p>
<p>We observed no significant CHD mortality prediction from serum vitamin B<sub>12</sub> levels. This could have occurred because our study was based on too few events and lacked the statistical power to detect a modest B<sub>12</sub> association with CHD mortality. Alternatively, vitamin B<sub>12</sub> has a relatively small effect on tHcy concentration, which could explain its non-significant association with mortality.<sup><xref ref-type="bibr" rid="bibr34-1741826711424568">34</xref></sup> Because of the high intra-individual variability of serum B<sub>12</sub> measurements, and as our measure of B<sub>12</sub> status was based on a single B<sub>12</sub> concentration, this could have diluted any observed association with risk of CHD mortality in our cohort as well as in others.<sup><xref ref-type="bibr" rid="bibr35-1741826711424568">35</xref></sup></p>
<p>To our best knowledge, our finding of a significant interaction between folate deficiency and hyperhomocysteinaemia on both CHD and all-cause mortality is novel. In BMES subjects with hyperhomocysteinaemia, having a folate deficiency did not further add to the risk of CHD or all-cause mortality. These findings indicate the need for additional measures other than addressing folate deficiency to reduce tHcy-associated vascular disease.<sup><xref ref-type="bibr" rid="bibr36-1741826711424568">36</xref></sup> These could include targeting of other components of the homocysteine metabolism pathway (such as vitamin B<sub>6</sub>) and factors such as diet quality, several disease states, and medications that are known to influence tHcy levels.<sup><xref ref-type="bibr" rid="bibr37-1741826711424568">37</xref>,<xref ref-type="bibr" rid="bibr38-1741826711424568">38</xref></sup></p>
<p>The strengths of this study are its prospective design, reasonable follow-up rate, long-term follow-up period, and ascertainment of mortality by validated NDI data. Several limitations, however, warrant discussion. Measurements of serum tHcy, folate, and vitamin B<sub>12</sub> were based on a single blood sample. This is likely to underestimate the associations with mortality due to regression dilution bias.<sup><xref ref-type="bibr" rid="bibr9-1741826711424568">9</xref></sup> Second, we cannot rule out the possibility that other unmeasured factors (e.g. subclinical vascular comorbidities) could have influenced our study findings.<sup><xref ref-type="bibr" rid="bibr28-1741826711424568">28</xref></sup> Finally, the number of CHD deaths was relatively small; this could have led to insufficient power to detect certain modest associations.</p>
<p>In summary, we have shown a strong predictive power of serum tHcy and folate for both all-cause and CHD mortality, after adjusting for traditional vascular risk factors and other confounders. Our findings confirm data from previous studies that have shown that hyperhomocysteinaemia is a prognostic marker of vascular disease and death, even if it may not be a direct cause of disease.<sup><xref ref-type="bibr" rid="bibr30-1741826711424568">30</xref></sup> A simple strategy of eating a diet that is rich in fruits, vegetables, and fortified grains and cereals, could help minimize the adverse vascular effects of elevated tHcy.
<fig id="fig1-1741826711424568" position="float"><label>Figure 1.</label><caption><p>Age-sex adjusted Kaplan−Meier survival curves for coronary heart disease (CHD) and all-cause mortality by diagnostic cut-points of: (a) serum homocysteine, tHcy, (elevated tHcy &gt;15 µmol/l); and (b) serum folate (folate deficiency &lt;11 nmol/l).</p></caption><graphic xlink:href="10.1177_1741826711424568-fig1.tif"/></fig></p>
</sec>
</body>
<back>
<sec id="sec10-1741826711424568"><title>Funding</title>
<p>This work was supported by the Australian National Health and Medical Research Council (grant numbers 974159, 991407, 211069, 262120).</p></sec>
<sec id="sec11-1741826711424568"><title>Conflicts of interest</title>
<p>None to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711424568"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Truelsen</surname><given-names>T</given-names></name><name><surname>Mahonen</surname><given-names>M</given-names></name><name><surname>Tolonen</surname><given-names>H</given-names></name><name><surname>Asplund</surname><given-names>K</given-names></name><name><surname>Bonita</surname><given-names>R</given-names></name><name><surname>Vanuzzo</surname><given-names>D</given-names></name></person-group>. <article-title>Trends in stroke and coronary heart disease in the WHO MONICA Project</article-title>. <source>Stroke</source> <year>2003</year>; <volume>34</volume>(<issue>6</issue>): <fpage>1346</fpage>–<lpage>1352</lpage>.</citation></ref>
<ref id="bibr2-1741826711424568"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Belanger</surname><given-names>AM</given-names></name><name><surname>Silbershatz</surname><given-names>H</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group>. <article-title>Prediction of coronary heart disease using risk factor categories</article-title>. <source>Circulation</source> <year>1998</year>; <volume>97</volume>(<issue>18</issue>): <fpage>1837</fpage>–<lpage>1847</lpage>.</citation></ref>
<ref id="bibr3-1741826711424568"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr.</suffix></name></person-group>. <article-title>Current and future directions of cardiovascular risk prediction</article-title>. <source>Am J Cardiol</source> <year>2006</year>; <volume>97</volume>(<issue>2A</issue>): <fpage>28A</fpage>–<lpage>32A</lpage>.</citation></ref>
<ref id="bibr4-1741826711424568"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>LL</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Rogers</surname><given-names>K</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Helfand</surname><given-names>M</given-names></name></person-group>. <article-title>Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis</article-title>. <source>Mayo Clin Proc</source> <year>2008</year>; <volume>83</volume>(<issue>11</issue>): <fpage>1203</fpage>–<lpage>1212</lpage>.</citation></ref>
<ref id="bibr5-1741826711424568"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daly</surname><given-names>C</given-names></name><name><surname>Fitzgerald</surname><given-names>AP</given-names></name><name><surname>O'Callaghan</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Cooney</surname><given-names>MT</given-names></name><name><surname>Graham</surname><given-names>IM</given-names></name></person-group>. <article-title>Homocysteine increases the risk associated with hyperlipidaemia</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>(<issue>2</issue>): <fpage>150</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr6-1741826711424568"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>DM</given-names></name><name><surname>King</surname><given-names>DE</given-names></name><name><surname>Mainous</surname><given-names>AG</given-names></name><name><surname>Geesey</surname><given-names>ME</given-names></name></person-group>. <article-title>Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>(<issue>2</issue>): <fpage>180</fpage>–<lpage>185</lpage>.</citation></ref>
<ref id="bibr7-1741826711424568"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marti-Carvajal</surname><given-names>AJ</given-names></name><name><surname>Sola</surname><given-names>I</given-names></name><name><surname>Lathyris</surname><given-names>D</given-names></name><name><surname>Salanti</surname><given-names>G</given-names></name></person-group>. <article-title>Homocysteine lowering interventions for preventing cardiovascular events</article-title>. <source>Cochrane Database Syst Rev</source> <year>2009</year>; <fpage>(4): CD006612</fpage>–<lpage>(4): CD006612</lpage>.</citation></ref>
<ref id="bibr8-1741826711424568"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christen</surname><given-names>WG</given-names></name><name><surname>Ajani</surname><given-names>UA</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group>. <article-title>Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual?</article-title> <source>Arch Intern Med</source> <year>2000</year>; <volume>160</volume>(<issue>3</issue>): <fpage>422</fpage>–<lpage>434</lpage>.</citation></ref>
<ref id="bibr9-1741826711424568"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dangour</surname><given-names>AD</given-names></name><name><surname>Breeze</surname><given-names>E</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Shetty</surname><given-names>PS</given-names></name><name><surname>Uauy</surname><given-names>R</given-names></name><name><surname>Fletcher</surname><given-names>AE</given-names></name></person-group>. <article-title>Plasma homocysteine, but not folate or vitamin B-12, predicts mortality in older people in the United Kingdom</article-title>. <source>J Nutr</source> <year>2008</year>; <volume>138</volume>(<issue>6</issue>): <fpage>1121</fpage>–<lpage>1128</lpage>.</citation></ref>
<ref id="bibr10-1741826711424568"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Refsum</surname><given-names>H</given-names></name><name><surname>Tverdal</surname><given-names>A</given-names></name><name><surname>Nygard</surname><given-names>O</given-names></name><name><surname>Nordrehaug</surname><given-names>JE</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><etal/></person-group>. <article-title>Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study</article-title>. <source>Am J Clin Nutr</source> <year>2001</year>; <volume>74</volume>(<issue>1</issue>): <fpage>130</fpage>–<lpage>136</lpage>.</citation></ref>
<ref id="bibr11-1741826711424568"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Ruijter</surname><given-names>W</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Assendelft</surname><given-names>WJ</given-names></name><name><surname>den Elzen</surname><given-names>WP</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study</article-title>. <source>BMJ</source> <year>2009</year>; <volume>338</volume>: <fpage>a3083</fpage>–<lpage>a3083</lpage>.</citation></ref>
<ref id="bibr12-1741826711424568"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Watt</surname><given-names>HC</given-names></name><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Weir</surname><given-names>DG</given-names></name><name><surname>McPartlin</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>JM</given-names></name></person-group>. <article-title>Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention</article-title>. <source>Arch Intern Med</source> <year>1998</year>; <volume>158</volume>(<issue>8</issue>): <fpage>862</fpage>–<lpage>867</lpage>.</citation></ref>
<ref id="bibr13-1741826711424568"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Lindemans</surname><given-names>J</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study</article-title>. <source>Arch Intern Med</source> <year>1999</year>; <volume>159</volume>(<issue>1</issue>): <fpage>38</fpage>–<lpage>44</lpage>.</citation></ref>
<ref id="bibr14-1741826711424568"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>Buring</surname><given-names>JE</given-names></name><name><surname>Shih</surname><given-names>J</given-names></name><name><surname>Matias</surname><given-names>M</given-names></name><name><surname>Hennekens</surname><given-names>CH</given-names></name></person-group>. <article-title>Homocysteine and risk of cardiovascular disease among postmenopausal women</article-title>. <source>JAMA</source> <year>1999</year>; <volume>281</volume>(<issue>19</issue>): <fpage>1817</fpage>–<lpage>1821</lpage>.</citation></ref>
<ref id="bibr15-1741826711424568"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giles</surname><given-names>WH</given-names></name><name><surname>Croft</surname><given-names>JB</given-names></name><name><surname>Greenlund</surname><given-names>KJ</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Kittner</surname><given-names>SJ</given-names></name></person-group>. <article-title>Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the third national health and nutrition examination survey, 1988⊟1994</article-title>. <source>Stroke</source> <year>1998</year>; <volume>29</volume>(<issue>12</issue>): <fpage>2473</fpage>–<lpage>2477</lpage>.</citation></ref>
<ref id="bibr16-1741826711424568"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ubbink</surname><given-names>JB</given-names></name><name><surname>Fehily</surname><given-names>AM</given-names></name><name><surname>Pickering</surname><given-names>J</given-names></name><name><surname>Elwood</surname><given-names>PC</given-names></name><name><surname>Vermaak</surname><given-names>WJ</given-names></name></person-group>. <article-title>Homocysteine and ischaemic heart disease in the Caerphilly cohort</article-title>. <source>Atherosclerosis</source> <year>1998</year>; <volume>140</volume>(<issue>2</issue>): <fpage>349</fpage>–<lpage>356</lpage>.</citation></ref>
<ref id="bibr17-1741826711424568"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Nieto</surname><given-names>FJ</given-names></name><name><surname>McGovern</surname><given-names>PG</given-names></name><name><surname>Tsai</surname><given-names>MY</given-names></name><name><surname>Malinow</surname><given-names>MR</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study</article-title>. <source>Circulation</source> <year>1998</year>; <volume>98</volume>(<issue>3</issue>): <fpage>204</fpage>–<lpage>210</lpage>.</citation></ref>
<ref id="bibr18-1741826711424568"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alfthan</surname><given-names>G</given-names></name><name><surname>Pekkanen</surname><given-names>J</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Pitkaniemi</surname><given-names>J</given-names></name><name><surname>Karvonen</surname><given-names>M</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study</article-title>. <source>Atherosclerosis</source> <year>1994</year>; <volume>106</volume>(<issue>1</issue>): <fpage>9</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr19-1741826711424568"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Byers</surname><given-names>TE</given-names></name><name><surname>Giles</surname><given-names>WH</given-names></name></person-group>. <article-title>Serum folate and chronic disease risk: findings from a cohort of United States adults</article-title>. <source>Int J Epidemiol</source> <year>1998</year>; <volume>27</volume>(<issue>4</issue>): <fpage>592</fpage>–<lpage>598</lpage>.</citation></ref>
<ref id="bibr20-1741826711424568"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Oijen</surname><given-names>MG</given-names></name><name><surname>Vlemmix</surname><given-names>F</given-names></name><name><surname>Laheij</surname><given-names>RJ</given-names></name><name><surname>Paloheimo</surname><given-names>L</given-names></name><name><surname>Jansen</surname><given-names>JB</given-names></name><name><surname>Verheugt</surname><given-names>FW</given-names></name></person-group>. <article-title>Hyperhomocysteinaemia and vitamin B<sub>12</sub> deficiency: the long-term effects in cardiovascular disease</article-title>. <source>Cardiology</source> <year>2007</year>; <volume>107</volume>(<issue>1</issue>): <fpage>57</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr21-1741826711424568"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bates</surname><given-names>CJ</given-names></name><name><surname>Mansoor</surname><given-names>MA</given-names></name><name><surname>Pentieva</surname><given-names>KD</given-names></name><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>GD</given-names></name></person-group>. <article-title>Biochemical risk indices, including plasma homocysteine, that prospectively predict mortality in older British people: the National Diet and Nutrition Survey of People Aged 65 Years and Over</article-title>. <source>Br J Nutr</source> <year>2010</year>; <volume>104</volume>(<issue>6</issue>): <fpage>1</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr22-1741826711424568"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attebo</surname><given-names>K</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>W</given-names></name></person-group>. <article-title>Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study</article-title>. <source>Ophthalmology</source> <year>1996</year>; <volume>103</volume>(<issue>3</issue>): <fpage>357</fpage>–<lpage>364</lpage>.</citation></ref>
<ref id="bibr23-1741826711424568"><label>23</label><citation citation-type="other"><comment>World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. <italic>J Hypertens</italic> 2003; 21(11): 1983–1992</comment>.</citation></ref>
<ref id="bibr24-1741826711424568"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Rosenberg</surname><given-names>IH</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><name><surname>Bowman</surname><given-names>BA</given-names></name><name><surname>Gunter</surname><given-names>EW</given-names></name><etal/></person-group>. <article-title>Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991⊟1994): population reference ranges and contribution of vitamin status to high serum concentrations</article-title>. <source>Ann Intern Med</source> <year>1999</year>; <volume>131</volume>(<issue>5</issue>): <fpage>331</fpage>–<lpage>339 [see comments]</lpage>.</citation></ref>
<ref id="bibr25-1741826711424568"><label>25</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>R</given-names></name></person-group>. <source>Principles of nutritional assessment</source>, <edition>1st edn</edition>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>, <year>1990</year>.</citation></ref>
<ref id="bibr26-1741826711424568"><label>26</label><citation citation-type="book"><collab>World Health Organization</collab>. <source>Manual of the international statistical classification of disease, injuries and causes of death</source>. <volume>Vol 1</volume>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>1977</year>.</citation></ref>
<ref id="bibr27-1741826711424568"><label>27</label><citation citation-type="book"><collab>World Health Organization</collab>. <source>International statistical classification of diseases and related health problems</source>, <publisher-loc>10th revision [ICD-10]. Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>1992</year>.</citation></ref>
<ref id="bibr28-1741826711424568"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Liew</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Leeder</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Retinal vascular calibre and the risk of coronary heart disease-related death</article-title>. <source>Heart</source> <year>2006</year>; <volume>92</volume>(<issue>11</issue>): <fpage>1583</fpage>–<lpage>1587</lpage>.</citation></ref>
<ref id="bibr29-1741826711424568"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magliano</surname><given-names>D</given-names></name><name><surname>Liew</surname><given-names>D</given-names></name><name><surname>Pater</surname><given-names>H</given-names></name><name><surname>Kirby</surname><given-names>A</given-names></name><name><surname>Hunt</surname><given-names>D</given-names></name><name><surname>Simes</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study</article-title>. <source>Aust N Z J Public Health</source> <year>2003</year>; <volume>27</volume>(<issue>6</issue>): <fpage>649</fpage>–<lpage>653</lpage>.</citation></ref>
<ref id="bibr30-1741826711424568"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Refsum</surname><given-names>H</given-names></name><name><surname>Nurk</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Ueland</surname><given-names>PM</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Bjelland</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease</article-title>. <source>J Nutr</source> <year>2006</year>; <volume>136</volume>(<issue>6 Suppl</issue>): <fpage>1731S</fpage>–<lpage>1740S</lpage>.</citation></ref>
<ref id="bibr31-1741826711424568"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nurk</surname><given-names>E</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Nygard</surname><given-names>O</given-names></name><name><surname>Refsum</surname><given-names>H</given-names></name><name><surname>Nilsen</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Changes in lifestyle and plasma total homocysteine: the Hordaland Homocysteine Study</article-title>. <source>Am J Clin Nutr</source> <year>2004</year>; <volume>79</volume>(<issue>5</issue>): <fpage>812</fpage>–<lpage>819</lpage>.</citation></ref>
<ref id="bibr32-1741826711424568"><label>32</label><citation citation-type="other"><comment>Sadeghpour A, Russel J, Flood V and Mitchell P. Australian Healthy Eating Index is associated with homocysteine, vitamin B<sub>12</sub> and folate biomarkers. International Society of Behavioral Nutrition and Physical Activity (ISBNPA) 2011 Annual Meeting. 2011</comment>.</citation></ref>
<ref id="bibr33-1741826711424568"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Rush</surname><given-names>D</given-names></name><name><surname>Rosenberg</surname><given-names>IH</given-names></name></person-group>. <article-title>Vitamin status and intake as primary determinants of homocysteinemia in an elderly population</article-title>. <source>JAMA</source> <year>1993</year>; <volume>270</volume>(<issue>22</issue>): <fpage>2693</fpage>–<lpage>2698</lpage>.</citation></ref>
<ref id="bibr34-1741826711424568"><label>34</label><citation citation-type="journal"><collab>Lowering blood homocysteine with folic acid based supplements</collab>. <article-title>meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration</article-title>. <source>BMJ</source> <year>1998</year>; <volume>316</volume>(<issue>7135</issue>): <fpage>894</fpage>–<lpage>898</lpage>.</citation></ref>
<ref id="bibr35-1741826711424568"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>J</given-names></name><name><surname>Beilby</surname><given-names>JP</given-names></name><name><surname>Knuiman</surname><given-names>MW</given-names></name><name><surname>Divitini</surname><given-names>M</given-names></name></person-group>. <article-title>Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia</article-title>. <source>BMJ</source> <year>2003</year>; <volume>326</volume>(<issue>7381</issue>): <fpage>131</fpage>–<lpage>131</lpage>.</citation></ref>
<ref id="bibr36-1741826711424568"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Jensen</surname><given-names>KR</given-names></name><name><surname>Carlquist</surname><given-names>JF</given-names></name><name><surname>Bair</surname><given-names>TL</given-names></name><name><surname>Horne</surname><given-names>BD</given-names></name><name><surname>Muhlestein</surname><given-names>JB</given-names></name></person-group>. <article-title>Effect of folic acid fortification of food on homocysteine-related mortality</article-title>. <source>Am J Med</source> <year>2004</year>; <volume>116</volume>(<issue>3</issue>): <fpage>158</fpage>–<lpage>164</lpage>.</citation></ref>
<ref id="bibr37-1741826711424568"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Welch</surname><given-names>GN</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group>. <article-title>Homocysteine and atherothrombosis</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>338</volume>(<issue>15</issue>): <fpage>1042</fpage>–<lpage>1050</lpage>.</citation></ref>
<ref id="bibr38-1741826711424568"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gopinath</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Flood</surname><given-names>VM</given-names></name><name><surname>Burlutsky</surname><given-names>G</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name></person-group>. <article-title>The associations between blood levels of homocysteine, folate, vitamin B<sub>12</sub>, and retinal vascular caliber</article-title>. <source>Am J Ophthalmol</source> <year>2009</year>; <volume>148</volume>(<issue>6</issue>): <fpage>902</fpage>–<lpage>909</lpage>.</citation></ref>
<ref id="bibr39-1741826711424568"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bostom</surname><given-names>AG</given-names></name><name><surname>Silbershatz</surname><given-names>H</given-names></name><name><surname>Rosenberg</surname><given-names>IH</given-names></name><name><surname>Selhub</surname><given-names>J</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women</article-title>. <source>Arch Intern Med</source> <year>1999</year>; <volume>159</volume>(<issue>10</issue>): <fpage>1077</fpage>–<lpage>1080</lpage>.</citation></ref>
<ref id="bibr40-1741826711424568"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Anand</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Boden-Albala</surname><given-names>B</given-names></name><name><surname>Stabler</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study</article-title>. <source>Stroke</source> <year>2004</year>; <volume>35</volume>(<issue>10</issue>): <fpage>2263</fpage>–<lpage>2269</lpage>.</citation></ref>
<ref id="bibr41-1741826711424568"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stehouwer</surname><given-names>CD</given-names></name><name><surname>Weijenberg</surname><given-names>MP</given-names></name><name><surname>van den Berg</surname><given-names>M</given-names></name><name><surname>Jakobs</surname><given-names>C</given-names></name><name><surname>Feskens</surname><given-names>EJ</given-names></name><name><surname>Kromhout</surname><given-names>D</given-names></name></person-group>. <article-title>Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1998</year>; <volume>18</volume>(<issue>12</issue>): <fpage>1895</fpage>–<lpage>1901</lpage>.</citation></ref>
<ref id="bibr42-1741826711424568"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Huerta</surname><given-names>JM</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name><name><surname>Patterson</surname><given-names>AM</given-names></name><name><surname>Lasheras</surname><given-names>C</given-names></name></person-group>. <article-title>Homocysteine increases the risk of mortality in elderly individuals</article-title>. <source>Br J Nutr</source> <year>2007</year>; <volume>97</volume>(<issue>6</issue>): <fpage>1138</fpage>–<lpage>1143</lpage>.</citation></ref>
<ref id="bibr43-1741826711424568"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marniemi</surname><given-names>J</given-names></name><name><surname>Jarvisalo</surname><given-names>J</given-names></name><name><surname>Toikka</surname><given-names>T</given-names></name><name><surname>Raiha</surname><given-names>I</given-names></name><name><surname>Ahotupa</surname><given-names>M</given-names></name><name><surname>Sourander</surname><given-names>L</given-names></name></person-group>. <article-title>Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population</article-title>. <source>Int J Epidemiol</source> <year>1998</year>; <volume>27</volume>(<issue>5</issue>): <fpage>799</fpage>–<lpage>807</lpage>.</citation></ref>
</ref-list>
</back>
</article>